Yong Zhang1, Tong Zang. 1. Department of Urology, General Hospital of Beijing Military Command, Beijing, China. hnandbjzy@gmail.com
Abstract
INTRODUCTION: Statins are cholesterol-lowering drugs that are widely used to prevent and treat atherosclerotic cardiovascular disease. It was found that statins can be associated with the occurrence of prostate cancer. However, no consensus has been concluded. MATERIALS AND METHODS: In the present study, we provide a refined meta-analysis on the association between statins and prostate cancers. Our objective is to offer a congruent recognition of the impact of statins on prostate cancer. RESULTS: Our refined analysis has included seven previous publications from the years 2005 to 2010. CONCLUSIONS: Based on the results, we concluded that there were associations for statin usage in preventing prostate cancer (OR 1.195, 95% CI 1.018-1.403, p = 0.029). Different from previous meta-analyses, our positive conclusion is primarily based on the recent new published literature, which supported the efficiency of statin use to control prostate cancer. More specific efforts for excluding the influence of other factors are crucial in further assessment of the efficiency of statin use.
INTRODUCTION: Statins are cholesterol-lowering drugs that are widely used to prevent and treat atherosclerotic cardiovascular disease. It was found that statins can be associated with the occurrence of prostate cancer. However, no consensus has been concluded. MATERIALS AND METHODS: In the present study, we provide a refined meta-analysis on the association between statins and prostate cancers. Our objective is to offer a congruent recognition of the impact of statins on prostate cancer. RESULTS: Our refined analysis has included seven previous publications from the years 2005 to 2010. CONCLUSIONS: Based on the results, we concluded that there were associations for statin usage in preventing prostate cancer (OR 1.195, 95% CI 1.018-1.403, p = 0.029). Different from previous meta-analyses, our positive conclusion is primarily based on the recent new published literature, which supported the efficiency of statin use to control prostate cancer. More specific efforts for excluding the influence of other factors are crucial in further assessment of the efficiency of statin use.
Authors: Amit M Algotar; Roxanna Behnejad; M Suzanne Stratton; Steven P Stratton Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-24 Impact factor: 4.254
Authors: Mohammed Habis; Kristen Wroblewski; Michael Bradaric; Nadia Ismail; S Diane Yamada; Lacey Litchfield; Ernst Lengyel; Iris L Romero Journal: PLoS One Date: 2014-08-13 Impact factor: 3.240
Authors: Xinjian Peng; Wenping Li; Liang Yuan; Rajendra G Mehta; Levy Kopelovich; David L McCormick Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240